“Before he was named Trump’s health secretary, Tom Price took a congressional trip to Australia and pressed officials to extend protections for drug companies in an international trade agreement,” ProPublica reports.
“Price’s lobbying abroad, which has not previously been reported, is another example of how his work in Congress could have benefitted his investment portfolio. He traded hundreds of thousands of dollars’ worth of shares in health-related companies while taking action on legislation and regulations affecting the industry. ProPublica previously reported that Price’s stock trades are said to be under investigation by federal prosecutors.”
Save to Favorites